A Selective N-Type Ca <sup>2+</sup> -Channel Blocker Prevents CA1 Injury 24 h following Severe Forebrain Ischemia and Reduces Infarction following Focal Ischemia

Alastair M. Buchan, S. Gertler, Hui Li, Dong Xue, Zhigao Huang, Karen E. Chaundy, Kimberley Barnes, Howard Lesiuk

Journal of Cerebral Blood Flow & Metabolism · 1994 · 142 citations · 39 references

DOIFull text

Open access

Concepts

Abstract

SNX-111 (NEUREX Corporation, Menlo Park, CA, U.S.A.) an ω-conopeptide, was tested for cytoprotection following normothermic ischemia using both a four-vessel occlusion model of severe forebrain ischemia and a model of transient middle cerebral artery occlusion focal ischemia. Adult male Wistar rats were subjected to 10 min of forebrain ischemia followed by 7 days of reperfusion. A single dose of SNX-111 (5 mg/kg) was injected intravenously following delays of either 6 or 24 h after reperfusion. For 11 rats treated with saline, there was 78 ± 13% CA1 neuronal injury (mean ± SD); for 11 given SNX-111 delayed by 6 h, injury was reduced to 35 ± 30% ( p &lt; 0.01); and remarkably, treatment delayed by 24 h ( n = 10), still resulted in protection, with only 50 ± 29% injury ( p &lt; 0.05). Adult male spontaneously hypertensive rats had transient occlusion of the right middle cerebral artery of 1.5- or 2-h duration followed by 22.5 or 22 h of reperfusion, respectively. Rats were randomly assigned to receive either saline or SNX-111 (5 mg/kg i.v.), with treatment starting immediately after reperfusion (1.5-h ischemic group) or at 1 h following the onset of ischemia (2-h ischemic group). In the 1.5-h ischemic group, saline-treated animals sustained 138 ± 32 mm 3 of neocortical infarction ( n = 9), and SNX-111 treatment resulted in an infarct reduction to 76 ± 25 mm 3 ( n = 9; p &lt; 0.001). In the 2-h ischemic group, saline-treated controls sustained 211 ± 51 mm 3 ( n = 6) of infarction, and SNX-111 infusion attenuated the infarct size to 126 ± 50 mm 3 ( n = 5; p &lt; 0.05). Because of the hypotensive effects of SNX-111, an additional SNX-111-treated group with intravenous norepinephrine blood pressure support was studied, using 2 h of focal ischemia and 22 h of reperfusion. In this group, combined treatment resulted in 141 ± 22 mm 3 of infarction ( n = 5; p &lt; 0.05). These data suggest that Ca 2+ fluxes through ω-conopeptide-sensitive N-type Ca 2+ channels are critically involved in the pathogenesis of selective neuronal death up to 24 h after ischemia in the hippocampus and that this conopeptide protection extends, even when given late, to neocortical infarct reduction.

References

39